A recent study published in The Lancet Oncology looked at the likelihood of survivors developing arm lymphedema and found that roughly 20% of breast cancer survivors were likely to develop the condition.
A recent study published in The Lancet Oncology looked at the likelihood of survivors developing arm lymphedema and found that roughly 20% of breast cancer survivors were likely to develop the condition.
Funded by Australia’s The National Breast Cancer Foundation, researchers found 72 studies with a pooled estimate of 16.9% (95% confidence interval [CI] 13.6–20.2) using Academic Search Elite, Cumulative Index to Nursing and Allied Health, Cochrane Central Register of Controlled Trials, and Medline, published from January 1, 2000 to June 30, 2012, that studied the incidence or risk factors for arm lymphedema after breast cancer. Arm lymphedema incidence seemed to increase for up to 2 years after diagnosis or surgery in 24 studies with time since diagnosis or surgery of 12 to <24 months; (18.9%, 14.2–24.7).
In 9 studies, the risk was highest when the cancer had been assessed with more than one diagnostic method (28.2%, 11.8–53.5). In 18 studies, risk of lymphedema was 4 times higher in women who underwent axillary lymph node dissection (19.9%, 13.5–28.2) than in those with sentinel-node biopsy (5.6%, 6.1–7.9). Risk factors with a high evidence level were being overweight and obese, and undergoing extensive surgery.
The researchers showed that at least 1 in 5 breast cancer survivors develop arm lymphedema. They urged the research community to continue looking at the contributing risk factors and to find prevention and management strategies.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More